KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Change in Receivables (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Change in Receivables data on record, last reported at $99.4 million in Q4 2025.

  • For Q4 2025, Change in Receivables rose 244.06% year-over-year to $99.4 million; the TTM value through Dec 2025 reached $347.3 million, up 249.75%, while the annual FY2025 figure was $347.3 million, 249.75% up from the prior year.
  • Change in Receivables reached $99.4 million in Q4 2025 per VRTX's latest filing, up from $59.9 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $251.6 million in Q1 2024 and bottomed at -$135.1 million in Q2 2024.
  • Average Change in Receivables over 5 years is $58.2 million, with a median of $55.8 million recorded in 2024.
  • Peak YoY movement for Change in Receivables: surged 1531.11% in 2021, then crashed 4758.62% in 2024.
  • A 5-year view of Change in Receivables shows it stood at $43.5 million in 2021, then plummeted by 123.45% to -$10.2 million in 2022, then crashed by 50.98% to -$15.4 million in 2023, then tumbled by 348.05% to -$69.0 million in 2024, then soared by 244.06% to $99.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were $99.4 million in Q4 2025, $59.9 million in Q3 2025, and $18.4 million in Q2 2025.